German Trial Finds Azelastine Nasal Spray Reduces COVID-19 Cases by Two-Thirds

Recent studies, including a randomized, controlled trial conducted by Saarland University in Germany, have shown that the over-the-counter antihistamine nasal spray azelastine significantly reduces the risk of COVID-19 infection. Participants using azelastine three times daily experienced about a threefold lower incidence of COVID-19 compared with those using a placebo, with infection rates of 2.2% versus 6.7%. Additionally, azelastine users had fewer symptomatic infections and shorter illness durations, and the spray also appeared effective against other respiratory viruses such as the common cold. Experts highlight azelastine's established safety profile, ease of use, and over-the-counter availability, making it a practical adjunct preventive measure, especially in high-risk settings. While promising, the current data come from a relatively small and healthy population, and larger studies are necessary to confirm these findings and evaluate broader applicability. Importantly, azelastine is not a substitute for vaccination or other proven preventive measures but may serve as an additional tool to reduce COVID-19 risk.